MENU
+Compare
CRNX
Stock ticker: NASDAQ
AS OF
Sep 23, 04:59 PM (EDT)
Price
$35.88
Change
+$2.16 (+6.41%)
Capitalization
3.38B

CRNX Crinetics Pharmaceuticals Forecast, Technical & Fundamental Analysis

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors... Show more

CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CRNX with price predictions
Sep 22, 2025

Aroon Indicator for CRNX shows an upward move is likely

CRNX's Aroon Indicator triggered a bullish signal on September 18, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 165 similar instances where the Aroon Indicator showed a similar pattern. In of the 165 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

CRNX moved above its 50-day moving average on August 22, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CRNX crossed bullishly above the 50-day moving average on August 27, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRNX advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CRNX moved out of overbought territory on September 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on September 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CRNX as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CRNX turned negative on September 19, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CRNX broke above its upper Bollinger Band on September 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.883) is normal, around the industry mean (19.858). P/E Ratio (0.000) is within average values for comparable stocks, (53.799). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.131). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. CRNX's P/S Ratio (2500.000) is slightly higher than the industry average of (344.050).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CRNX is expected to report earnings to -123 cents per share on November 06

Crinetics Pharmaceuticals CRNX Stock Earnings Reports
Q3'25
Est.
$-1.23
Q2'25
Missed
by $0.13
Q1'25
Missed
by $0.11
Q4'24
Est.
$-0.88
Q3'24
Missed
by $0.05
The last earnings report on August 07 showed earnings per share of -123 cents, missing the estimate of -110 cents. With 1.38M shares outstanding, the current market capitalization sits at 3.38B.
A.I. Advisor
published General Information

General Information

a developer of therapeutics for endocrine-related diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
6055 Lusk Boulevard
Phone
+1 858 450-6464
Employees
290
Web
https://www.crinetics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FLMAX10.400.05
+0.48%
Meeder Muirfield Adviser
OCRDX21.040.07
+0.33%
Invesco Rising Dividends C
AGCHX19.390.06
+0.31%
American Century Global Small Cap C
FLCNX37.52N/A
N/A
Fidelity Contrafund K6
FTVNX33.80-0.15
-0.44%
FullerThaler Behav Md-Cp Val Investor

CRNX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-0.56%
XNCR - CRNX
63%
Loosely correlated
+0.97%
DYN - CRNX
57%
Loosely correlated
+2.36%
NRIX - CRNX
57%
Loosely correlated
-0.12%
IDYA - CRNX
56%
Loosely correlated
+0.70%
VRDN - CRNX
56%
Loosely correlated
+0.62%
More